<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7501082\results\search\testTrace\results.xml">
  <result pre="10.1016/j.bcp.2020.114225114225 : Perspective Role of proteolytic enzymes in the COVID-19" exact="infection" post="and promising therapeutic approaches GioiaMagdaaâ�ŽCiaccioChiaraaâ�ŽCalligariPaolobDe SimoneGiovannacSbardellaDiegodTundoGraziadFasciglioneGiovanni FrancescoaDi MasiAlessandracDi PierroDonatoaBocediAlessiobAscenziPaoloceColettaMassimoaâ�Ž[a],"/>
  <result pre="community has come together to understand the mechanisms underlying the" exact="infection" post="and the virulence of SARS-CoV-2 virus, as well as"/>
  <result pre="the elucidation of the pathogenetic features of this novel viral" exact="infection" post="in search for effective therapeutic approaches [1]. Little is"/>
  <result pre="that this enzyme plays a dominant relevance in SARS-CoV-2 viral" exact="infection" post="[13], [19], [20], [21]. Therefore, furin may play either"/>
  <result pre="located. A key discovery in understanding the mechanism of SARS-CoV-2" exact="infection" post="concerns the role of the androgen-responsive transmembrane serine protease"/>
  <result pre="life cycle (such as viral formation, progression of the viral" exact="infection" post="and reproduction of virions). Overall, two very attractive processes"/>
  <result pre="proteins, which are required for the progression of the viral" exact="infection" post="and replication of viruses. 2 Activation of spike (S)"/>
  <result pre="[26] (Fig. 3B). The globular N-terminal S1 subunit mediates the" exact="infection" post="of receptor-expressing host cells; it contains a receptor-binding domain"/>
  <result pre="L have also been shown to be involved in SARS-CoV-2" exact="infection" post="[20], [11]. The formation of the S2 fragment and"/>
  <result pre="of arthritic mice. [176] Dec-Arg-Val-Lys-Arg-CMK 1000 Topical uses in the" exact="treatment" post="of HPV skin infections. [53], [57], [177] Antiviral activityÂ"/>
  <result pre="particles. [19] Phac-Arg-Val-Arg-Amba 810 Reduces FPV propagation in a long-term" exact="infection" post="test. [61] Suppresses the activation of HA0 in fowl"/>
  <result pre="[44], Chikungunya virus [56], chronic HBV, influenza A, Ebola virus" exact="infection" post="[55] and papilloma virus [57]. Recently, the efficacy of"/>
  <result pre="these molecules remain limited to topical applications, such as the" exact="treatment" post="of papillomavirus (HPV) skin infections [53], [45]. However, the"/>
  <result pre="able to reduce feline panleukopenia virus propagation in a long-term" exact="infection" post="test (25Â Î¼M of inhibitor over a period of"/>
  <result pre="Structure-function A key discovery in understanding the mechanism of SARS-CoV-2" exact="infection" post="concerns the role of the androgen-responsive transmembrane serine protease"/>
  <result pre="United States), suggest that the incidence and severity of the" exact="diagnosis" post="of COVID-19 and other TMPRSS2-dependent viral infections are higher"/>
  <result pre="the androgen-dependent TMPRSS2 expression has led to speculate that the" exact="prevalence" post="of COVID-19 cases in men may possibly be related"/>
  <result pre="cells [84], [19], [15]. Furthermore, TMPRSS2-deficient mice had minimal initial" exact="infection" post="when infected with specific influenza A virus strains, SARS-CoV"/>
  <result pre="with no significant adverse effects, it could be used for" exact="treatment" post="of coronavirus infections as an inhibitor of TMPRSS2 [64],"/>
  <result pre="Similarly, the Nafamostat, a structural analog of Camostat, blocks SARS-CoV-2" exact="infection" post="of human lung cells with 15-fold higher efficiency than"/>
  <result pre="it a good compound to enter clinical trials for COVID-19" exact="treatment" post="[20]. A structural model of TMPRSS2-Camostat complex suggests that"/>
  <result pre="inhibitors may show several pitfalls, it is certainly a potential" exact="treatment" post="option against SARS-CoV-2 that should be further pursued [103]."/>
  <result pre="by inhibiting the cellular host TMPRSS2 (see above sections), more" exact="testing" post="is required before it can possibly be labelled as"/>
  <result pre="can possibly be labelled as an effective therapy for the" exact="treatment" post="of COVID-19. Considering the central role of TMPRSS2 in"/>
  <result pre="the phytochemical geniposide; this TMPRSS2 inhibitor should be validated for" exact="treatment" post="of coronavirus infection as it does not show toxicity"/>
  <result pre="this TMPRSS2 inhibitor should be validated for treatment of coronavirus" exact="infection" post="as it does not show toxicity in humans, since"/>
  <result pre="action of nitric oxide (NO) has been reported for the" exact="treatment" post="of several DNA and RNA virus families [106]. Therefore,"/>
  <result pre="It is worth noting that the urgency for an effective" exact="treatment" post="against COVID-19 has deeply stimulated the scientific community to"/>
  <result pre="employed. Over one decade ago, in an interesting anti-SARS drug" exact="screening" post="research, 59,363 compounds were docked, 93 were selected for"/>
  <result pre="=Â 0.040Â Î¼M, respectively), being also effective on the anti-SARS-CoV-2" exact="infection" post="activity in cell culture (EC50Â =Â 0.53Â Î¼M and"/>
  <result pre="inhibition of SARS-CoV-2 Mpro. Hereafter, a series of in silico" exact="screening" post="on these compounds is reported [131], [132], [133], [134],"/>
  <result pre="[139], [140]. A first interesting approach was carried out by" exact="screening" post="an impressive number (more than 606 million) of compounds."/>
  <result pre="and Zinc databases, were also analyzed by bioinformatics approach, virtual" exact="screening" post="tools and molecular dynamics. The best three molecules were"/>
  <result pre="or for protein inhibition in other human pathogens. 4.3.1.2.1 Virtual" exact="screening" post="In an interesting study two libraries of drugs were"/>
  <result pre="alprazolam, trovafloxacin, sarafloxacin and ethyl biscoumacetate [142]. Alternatively, a virtual" exact="screening" post="of FDA-approved drugs was performed against the SARS-CoV-2 Mpro,"/>
  <result pre="against SARS-CoV-2 Mpro and tested clinically in China for COVID-19" exact="treatment" post="[147]. Viomycin, a nonribosomal peptide with antibiotic properties and"/>
  <result pre="a nonribosomal peptide with antibiotic properties and administered for the" exact="treatment" post="of Mycobacterium tuberculosis infection, was docked for Mpro embedding"/>
  <result pre="of SARS-CoV-2 Mpro were also identified by a structure-guided virtual" exact="screening" post="approach using inhibitor N3 as a starting reference. Interestingly,"/>
  <result pre="inhibition of different types of proteases [150]. A structure-based virtual" exact="screening" post="on SARS-CoV-2 Mpro was also performed using the ChEMBL"/>
  <result pre="eszopiclone (âˆ’10.0Â kcal/mol) (Fig. 7F) a drug used for the" exact="treatment" post="of insomnia [151]. Further, the antibiotic talampicillin and the"/>
  <result pre="talampicillin and the anti-psychotic lurasidone have been identified by virtual" exact="screening" post="as potential drugs worth being tested against SARS-CoV-2 MPro"/>
  <result pre="same work, umifenovir, together with montelukast, a drug for the" exact="treatment" post="of allergies and the prevention of asthma attacks, showed"/>
  <result pre="with âˆ’5.0Â kcal/mol and âˆ’5.9Â kcal/mol, respectively [153]. 4.3.1.2.2 Experimental" exact="testing" post="An important set of promising molecules with inhibitory effect"/>
  <result pre="applications. Inhibitor EC50 (ÂµM) Application Refs. Baicalin 27.87 Respiratory tract" exact="infection" post="[154] Baicalein 2.94 Respiratory tract infection [154] Chloroquine 2.71/5.47"/>
  <result pre="Baicalin 27.87 Respiratory tract infection [154] Baicalein 2.94 Respiratory tract" exact="infection" post="[154] Chloroquine 2.71/5.47 Malaria [155], [162] Hydroxychloroquine 0.7/4.51 Malaria"/>
  <result pre="inhibitory function on NF-kB signalling and inflammatory responses during viral" exact="infection" post="[158]. Cinanserin was considered an inhibitor of SARS-CoV (IC50Â"/>
  <result pre="=Â 5.47Â Î¼M vs 0.7Â Î¼M in the Vero cell" exact="infection" post="model, respectively) [162], though displaying suboptimal affinity scores ofÂ"/>
  <result pre="the drugs and compounds reported previously were employed in the" exact="treatment" post="of COVID-19. Most of the drugs, identified by molecular"/>
  <result pre="ribavirin, and lopinavir/ritonavir in patients without autoimmune diseases, hepatitis, HIV" exact="infection" post="is not clear. Remdesivir is an experimental drug for"/>
  <result pre="is not clear. Remdesivir is an experimental drug for the" exact="treatment" post="of Ebolavirus, so cardiovascular effects and toxicities are unknown,"/>
  <result pre="new drugs targeting specific activities of the virus and its" exact="infection" post="cycle is essential [175]. Considerable progress has been made"/>
  <result pre="on the biological molecular mechanisms of SARS-CoV-2, requiring the virus" exact="isolation" post="in vitro and its cultivation, as it is usually"/>
  <result pre="employed to verify the proof of principle of the viral" exact="infection" post="process. However, it may not usually be practical, demanding"/>
  <result pre="while targeting the intracellular virus cycle does not avoid the" exact="infection" post="of cells (only impairing the further diffusion of virions),"/>
  <result pre="lesson, which emerges from this pandemic situation, is that drugs" exact="treatment" post="and new studies about SARS-CoV-2 macromolecular targets are extremely"/>
  <result pre="References References 1MorseJ.S.LalondeT.XuS.LiuW.R.Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoVChemBioChem.21202073073810.1002/cbic.20200004732022370"/>
  <result pre="proven protease inhibitorCell181202027128010.1016/j.cell.2020.02.05232142651 20HoffmannM.SchroederS.Kleine-WeberH.MÃ¼llerM.A.DrostenC.PÃ¶hlmannS.Nafamostat mesylate blocks acrivation of SARS-CoV-2: new" exact="treatment" post="option for COVID-19Antimicrob. Agents Chemother.642020e00754e82010.1128/AAC.00754-2032312781 21JaimesJ.A.AndrÃ©N.M.ChappieJ.S.MilletJ.K.WhittakerG.R.Phylogenetic analysis and structural"/>
  <result pre="chloroalkyl ketonesVirology1721989253110.1016/0042-6822(89)90103-72773317 55PangY.J.TanX.J.LiD.M.ZhengZ.H.LeiR.X.PengX.M.Therapeutic potential of furin inhibitors for the chronic" exact="infection" post="of hepatitis B virusLiver Int.3320131230123810.1111/liv.1218523617302 56OzdenS.Lucas-HouraniM.CeccaldiP.E.BasakA.ValentineM.BenjannetS.HamelinJ.JacobY.MamchaouiK.MoulyV.DesprÃ¨sP.GessainA.Butler-BrowneG.ChrÃ©tienM.TangyF.VidalainP.O.SeidahN.G.Inhibition of Chikungunya virus"/>
  <result pre="infection of hepatitis B virusLiver Int.3320131230123810.1111/liv.1218523617302 56OzdenS.Lucas-HouraniM.CeccaldiP.E.BasakA.ValentineM.BenjannetS.HamelinJ.JacobY.MamchaouiK.MoulyV.DesprÃ¨sP.GessainA.Butler-BrowneG.ChrÃ©tienM.TangyF.VidalainP.O.SeidahN.G.Inhibition of Chikungunya virus" exact="infection" post="in cultured human muscle cells by furin inhibitors: impairment"/>
  <result pre="site in the Spike protein of SARS-CoV-2 is essential for" exact="infection" post="of human lungCells, Molecular Cell.78202077978410.1016/j.molcel.2020.04.02232362314 61BeckerG.L.SielaffF.ThanM.E.LindbergI.RouthierS.DayR.LuY.GartenW.SteinmetzerT.Potent inhibitors of Furin"/>
  <result pre="expression in lungMol. Cell. Endocrinol.3172010142410.1371/journal.pone.018416620035825 66ShenL.W.MaoH.J.WuY.L.TanakaY.ZhangW.TMPRSS2: a potential target for" exact="treatment" post="of influenza virus and coronavirus infectionsBiochimie142201711028778717 67MadjidM.Safavi-NaeiniP.SolomonS.D.VardenyO.Potential effects of"/>
  <result pre="protein by the transmembrane protease TMPRSS2J. Virol.842010126581266410.1128/JVI.01542-1020926566 84KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous" exact="treatment" post="of human bronchial epithelial cells with serine and cysteine"/>
  <result pre="filovirus entry, Antivir. Res. 116 (2015) 76â€&quot;84, doi: 10.1016/j.antiviral.2015.01.011. 90RahmanN.BasharatZ.YousufM.CastaldoG.RastrelliL.KhanH.Virtual" exact="screening" post="of natural products against type II transmembrane serine protease"/>
  <result pre="anti-SARS drugsScience30020031763176710.1126/science.108565812746549 121LiuW.MorseJ.S.LalondeT.XuS.Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoVChemBioChem21202073073810.1002/cbic.20200004732022370"/>
  <result pre="of a novel family of SARS-CoV protease inhibitors by virtual" exact="screening" post="and 3D-QSAR studiesJ. Med. Chem.4920063485349510.1021/jm050852f16759091 127HagarM.AhmedH.A.AljohaniG.AlhaddadO.A.Investigation of some antiviral"/>
  <result pre="Dyn.202011210.1080/07391102.2020.1761883 131FischerA.SellnerM.NeranjanS.SmieÅ¡koM.LillM.A.Potential inhibitors for novel Coronavirus protease identified by virtual" exact="screening" post="of 606 million compoundsInt. J. Mol. Sci.212020e362610.3390/ijms21103626 132GuptaS.SinghA.K.KushwahaP.P.PrajapatiK.S.ShuaiM.SenapatiS.KumarS.Identification of"/>
  <result pre="protease from a library of marine natural products: a virtual" exact="screening" post="and molecular modeling studyMar. Drugs18202022510.3390/md18040225 142GimenoA.Mestres-TruyolJ.Ojeda-MontesM.J.MacipG.Saldivar-EspinozaB.Cereto-MassaguÃ©A.PujadasG.Garcia-VallvÃ©S.Prediction of novel inhibitors"/>
  <result pre="145Al-KhafajiK.Al-DuhaidahawiD.Taskin TokT.Using integrated computational approaches to identify safe and rapid" exact="treatment" post="for SARS-CoV-2J. Biomol. Struct. Dyn.20201910.1080/07391102.2020.1764392 146DasS.SarmahS.LyndemS.Singha RoyA.An investigation into"/>
  <result pre="of potential molecules against COVID-19 main protease through structure-guided virtual" exact="screening" post="approachJ. Biomol. Struct. Dyn.202011910.1080/07391102.2020.1768151 151TsujiM.Potential anti-SARS-CoV-2 drug candidates identified"/>
  <result pre="Biomol. Struct. Dyn.202011910.1080/07391102.2020.1768151 151TsujiM.Potential anti-SARS-CoV-2 drug candidates identified through virtual" exact="screening" post="of the ChEMBL database for compounds that target the"/>
  <result pre="proteaseFEBS Open Bio.102020995100410.1002/2211-5463.12875 152ElmezayenA.D.Al-ObaidiA.ÅžahinA.T.YelekÃ§iK.Drug repurposing for coronavirus (COVID-19): in silico" exact="screening" post="of known drugs against coronavirus 3CL hydrolase and protease"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.620201610.1038/s41421-020-0156-032194981 156MaC.SaccoM.D.HurstB.TownsendJ.A.HuY.SzetoT.ZhangX.TarbetB.MartyM.T.ChenY.WangJ.Boceprevir, GC-376, and calpain inhibitors II,"/>
  <result pre="M Protease Inhibitors Encoded by SARS-CoV-2Antimicrob. Agents Chemother.642020e00872e92010.1128/AAC.00872-2032669265 158LiZ.LiX.HuangY.-Y.WuY.ZhouL.LiuR.WuD.ZhangL.LiuH.XuX.ZhangY.CuiJ.Xin WangX.LuoH.-B.FEP-based" exact="screening" post="prompts drug repositioning against COVID-19BioRxiv202010.1101/2020.03.23.004580 159YangQ.ChenL.HeX.GaoZ.ShenX.BaiD.Design and synthesis of"/>
  <result pre="and the cardiovascular system: implications for risk assessment, diagnosis, and" exact="treatment" post="optionsCardiovasc. Res.1161020201666168710.1093/cvr/cvaa10632352535 166LiuX.WangX.J.Potential inhibitors against 2019-nCoV coronavirus M protease"/>
  <result pre="J. Pediatr.87202043344210.1007/s12098-020-03292-132338347 169VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 170ZouL.DaiL.ZhangX.ZhangZ.ZhangZ.Hydroxychloroquine and chloroquine: a potential and"/>
  <result pre="and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 170ZouL.DaiL.ZhangX.ZhangZ.ZhangZ.Hydroxychloroquine and chloroquine: a potential and controversial" exact="treatment" post="for COVI19Arch Pharm Res.438202076577210.1007/s12272-020-01258-732740801 171ShihH.I.WuC.J.TuY.F.ChiC.Y.Fighting COVID-19: a quick review"/>
  <result pre="Dyn.20201910.1080/07391102.2020.1754293 176DuboisC.Use of furin and furin-like protease inhibitors in the" exact="treatment" post="of inflammatory or matrix remodelling diseases patentPatent US01273962004 177RemacleA.G.GawlikK.GolubkovV.S.CadwellG.W.LiddingtonR.C.CieplakP.MillisS.Z.DesjardinsR.RouthierS.YuanX.W.NeugebauerW.A.DayR.StronginaA.Y.Selective"/>
 </snippets>
</snippetsTree>
